Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline
Summary
Every plant, animal, and human being hosts a thriving ecosystem of microbes vital to its health, said Kehe, Chief Scientific Officer of Concerto. To maximize its impact, Concerto will collaborate with biotech and pharma companies to discover a suite of ensembles that could transform industries as diverse as healthcare, agriculture, and household products.Concertos unique knowledge of the interplay among microbes catapults our whole industry toward a frontier of new products spanning disease treatment, consumer goods, and crop science, said Ackerman, CEO of Concerto. Using kChip data, Concerto can map interaction networks that reveal a new class of products it calls ensemblescombinations of microbes that work in concert to shepherd damaged microbial communities to health. Since launching Concerto in 2020, the team has assembled a human skin microbe biobank, measured >6 million interactions with kChip, and discovered an ensemble that corrects the microbial deficiency underlying atopic dermatitis. We accelerate the scaling of our portfolio companies through the formation of spinouts or joint ventures to address additional markets, industries, or geographies.